[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 216
Citations 0
Comment & Response
October 2016

Study on the Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell CarcinomaNot a Case-Control Study

Author Affiliations
  • 1Melanoma Unit, Dermatology Department, Hospital Clínic, Universidad de Barcelona, Barcelona, Spain
  • 2Institut d’investigacions biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
  • 3Clinical Epidemiology Unit, Istituto Dermopatico dell’Immacolata-IRCCS, Rome, Italy
  • 4Dermatology Department, Instituto Dermatológico GlobalDerm, Córdoba, Spain
JAMA Dermatol. 2016;152(10):1172-1173. doi:10.1001/jamadermatol.2016.2428

To the Editor We read with concern the article by Mohan et al.1 First, this is not a case-control study in which participants are sampled based on the presence (case) or absence (control) of a given disease. Instead this is a retrospective cohort study of patients exposed or not exposed to vismodegib.

In addition, non–basal cell carcinoma (BCC) secondary cancers were defined as being associated with vismodegib therapy if they were diagnosed at least 2 weeks after the first exposure to vismodegib. Is it possible to include events occurring so early after treatment?

First Page Preview View Large
First page PDF preview
First page PDF preview